<DOC>
	<DOCNO>NCT00003229</DOCNO>
	<brief_summary>RATIONALE : Vaccines make person 's white blood cell melanoma cell may make body build immune response kill tumor cell . PURPOSE : Randomized phase I/II trial study effectiveness vaccine therapy make white blood cell melanoma cell treat patient metastatic melanoma undergo surgery lymph node tumor removal .</brief_summary>
	<brief_title>Vaccine Therapy Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery Lymph Node Tumor Removal</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety toxicity intravenous injection autologous culture dendritic cell pulse either gp100 tyrosinase peptides autologous melanoma tumor cell lysates patient metastatic melanoma . II . Determine whether treatment melanoma tumor antigen pulse autologous dendritic cell result increase vitro tumor specific cytotoxic T-cell response . III . Determine whether treatment induce positive skin test response tumor antigen . IV . Evaluate disease free overall survival patient . OUTLINE : This randomize , dose escalation study . Approximately 1-2 week follow surgical lymphadenectomy , patient undergo leukapheresis collect dendritic cell divide 3 group . Group A consist patient without adequate tumor preparation tumor lysate tumor express tyrosinase gp100 type HLA-A1 , A2 , A3 . Group B consist patient adequate tumor lysate preparation type HLA-A1 , A2 , A3 ( require peptide pulse protocol ) . Group C patient adequate tumor eligible peptide pulse protocol . Group A patient receive autologous dendritic cell pulse appropriate peptide antigen . Group B patient treat autologous dendritic cell pulse autologous tumor cell lysates . Group C patient randomize receive dendritic cell pulse either peptide antigen tumor lysate . All patient administer intravenous active immunotherapy 4 monthly interval . The dose immunization escalate cohort three patient accrue group mention . Each immunization dose level follow three day interleukin-2 administer subcutaneously twice daily . Patients follow least 5 year survival . PROJECTED ACCRUAL : There 100 patient accrue study 2 year . There 50 , 20 , 30 patient group A , B , C , respectively .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic melanoma involve cervical , axillary , inguinal , groin , iliac lymph node All gross disease resect time surgical lymphadenectomy No distant metastases PATIENT CHARACTERISTICS : Age : 18 75 Performance status : ECOG 01 Life expectancy : At least 6 month Hematopoietic : Platelet count least 100,000/mm3 Hemoglobin least 8 g/dL Hepatic : Bilirubin great 1.4 mg/dL AST ALT great 1.5 time normal No active hepatitis Renal : Creatinine great 1.4 mg/dL Cardiovascular : No congestive heart failure , unstable angina , current symptomatic arrhythmia Other : HIV negative No autoimmune disease ( e.g. , lupus erythematosus , multiple sclerosis , ankylose spondylitis ) No condition would consider contraindication surgery Not pregnant nursing Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : At least 4 week since prior therapy melanoma Biologic therapy : At least 3 month since prior interferon therapy Chemotherapy : No active immunosuppression due prior chemotherapy Endocrine therapy : No active immunosuppression due steroid therapy Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
</DOC>